A phase I study of RMC-035 to evaluate safety in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs RMC 035 (Primary)
- Indications Acute kidney injury; Preeclampsia; Radiation injuries
- Focus Adverse reactions; Pharmacokinetics
- Sponsors A1M Pharma AB
- 09 Apr 2019 According to an A1M Pharma AB media release, the first subject has been dosed in this trial. The results of the first phases are expected to be available in about six months.
- 21 Mar 2019 According to an A1M Pharma AB media release, the study will begin with screening of healthy subjects for 1-2 weeks, followed by dosing in the first dose group. The results of the first phases anticipated approximately six months after dosing the first participant.
- 21 Mar 2019 Status changed from planning to recruiting, as reported in an A1M Pharma AB media release.